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Abstract
Local skin heating is used to assess microvascular function in clinical populations because NO is required for full 
expression of the response; however, controversy exists as to the precise NO synthase (NOS) isoform producing 
NO. Human aging is associated with attenuated cutaneous vasodilation but little is known about the middle aged, 
an age cohort used for comparison with clinical populations. We hypothesized that endothelial NOS (eNOS) is the 
primary isoform mediating NO production during local heating, and eNOS-dependent vasodilation would be 
reduced in middle-aged skin. Vasodilation was induced by local heating (42°C) and during acetylcholine dose-
response (ACh-DR: 0.01, 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 mmol/l) protocols. Four microdialysis fibers were placed 
in the skin of 24 men and women; age cohorts were 12 middle-aged (53 ± 1 yr) and 12 young (23 ± 1 yr). Sites 
served as control, nonselective NOS inhibited [NG-nitro-l-arginine methyl ester (l-NAME)], inducible NOS (iNOS) 
inhibited (1400W), and neuronal NOS (nNOS) inhibited (Nω-propyl-l-arginine). After full expression of the local 
heating response, l-NAME was perfused at all sites. Cutaneous vascular conductance was measured and 
normalized to maximum (%CVCmax: Nitropress). l-NAME reduced %CVCmax at baseline, all phases of the local 
heating response, and at all ACh concentrations compared with all other sites. iNOS inhibition reduced the initial 
peak (53 ± 2 vs. 60 ± 2%CVCmax; P < 0.001); however, there were no other differences between control, 
nNOS-, and iNOS-inhibited sites during the phases of local heating or ACh-DR. When age cohorts were compared, 
NO-dependent vasodilation during local heating (52 ± 6 vs. 68 ± 4%CVCmax; P = 0.013) and ACh perfusion 
(50 mmol/l: 83 ± 3 vs. 93 ± 2%CVCmax; 100 mmol/l: 83 ± 4 vs. 92 ± 3%CVCmax; both P = 0.03) were 
reduced in middle-aged skin. There were no differences in NOS isoform expression obtained from skin biopsy 
samples between groups (all P > 0.05). These data suggest that eNOS mediates the production of NO during local 
heating and that cutaneous vasodilation is attenuated in middle-aged skin.
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skin heating is used to assess microvascular function in clinical
populations because NO is required for full expression of the re-
sponse; however, controversy exists as to the precise NO synthase
(NOS) isoform producing NO. Human aging is associated with
attenuated cutaneous vasodilation but little is known about the middle
aged, an age cohort used for comparison with clinical populations. We
hypothesized that endothelial NOS (eNOS) is the primary isoform
mediating NO production during local heating, and eNOS-dependent
vasodilation would be reduced in middle-aged skin. Vasodilation was
induced by local heating (42°C) and during acetylcholine dose-
response (ACh-DR: 0.01, 0.1, 1.0, 5.0, 10.0, 50.0, 100.0 mmol/l)
protocols. Four microdialysis fibers were placed in the skin of 24 men
and women; age cohorts were 12 middle-aged (53  1 yr) and 12
young (23  1 yr). Sites served as control, nonselective NOS
inhibited [NG-nitro-L-arginine methyl ester (L-NAME)], inducible
NOS (iNOS) inhibited (1400W), and neuronal NOS (nNOS) inhibited
(N-propyl-L-arginine). After full expression of the local heating
response, L-NAME was perfused at all sites. Cutaneous vascular
conductance was measured and normalized to maximum (%CVCmax:
Nitropress). L-NAME reduced %CVCmax at baseline, all phases of
the local heating response, and at all ACh concentrations compared
with all other sites. iNOS inhibition reduced the initial peak (53  2
vs. 60  2%CVCmax; P  0.001); however, there were no other
differences between control, nNOS-, and iNOS-inhibited sites during
the phases of local heating or ACh-DR. When age cohorts were
compared, NO-dependent vasodilation during local heating (52  6
vs. 68  4%CVCmax; P  0.013) and ACh perfusion (50 mmol/l:
83  3 vs. 93  2%CVCmax; 100 mmol/l: 83  4 vs. 92 
3%CVCmax; both P  0.03) were reduced in middle-aged skin. There
were no differences in NOS isoform expression obtained from skin
biopsy samples between groups (all P  0.05). These data suggest
that eNOS mediates the production of NO during local heating and
that cutaneous vasodilation is attenuated in middle-aged skin.
inducible nitric oxide synthase; neuronal nitric oxide synthase; skin
blood flow; vascular aging
THE CUTANEOUS MICROVASCULATURE provides an easily accessi-
ble, minimally invasive circulation to examine vascular func-
tion (1, 3, 11). Several methods are available to locally induce
vasodilation in the cutaneous microvasculature. Direct local
warming of the skin just below the pain threshold to 42°C
elicits near maximal vasodilation in young, healthy individuals
because at this temperature the vascular smooth muscle is
completely relaxed and gives a highly reproducible skin blood
flow response. This protocol (17, 23, 24) has been increasingly
utilized to examine microvascular dysfunction in clinical pop-
ulations (10, 17, 25, 32). The skin blood flow response to local
heating is biphasic, consisting of an initial sensory nerved-
mediated rapid increase in skin blood flow, followed by a
slower secondary rise to a plateau that is 70% reliant on
NO-dependent mechanisms (14, 17, 24). In addition to local
heating, perfusion of the endothelium-dependent agonist ace-
tylcholine (ACh) in a dose-dependent manner can be utilized to
examine receptor-mediated endothelial function (21, 32).
All three NOS isoforms (endothelial, neuronal, and induc-
ible) have been purported to contribute to the skin local heating
response in different patient populations (18, 34). Significant
controversy exists as to which is the primary isoform mediating
the production of NO during the plateau phase of the skin local
heating response. We have recently shown that an upregulation
of the proinflammatory signaling mediator inducible nitric
oxide synthase (iNOS) contributes to attenuated NO-dependent
cutaneous vasodilation in essential hypertensive humans (32)
potentially through S-nitrosylation of arginase 1, which com-
petes for the NOS substrate L-arginine (30). Whether iNOS
may contribute to the local heating response in nonpathological
states is unclear.
Changes in both resistance vessel structure and decrements
in NO-mediated dilation occur with aging and the development
of cardiovascular disease (7, 29). Primary human aging, even
in the absence of cardiovascular disease, is associated with
attenuated skin blood flow responses including reduced plateau
and relative NO-dependent cutaneous vasodilation during local
heating and perfusion of endothelium-dependent receptor ago-
nists (19, 26). However, little is known about these mecha-
nisms along the aging continuum, specifically, in the middle-
aged cohort often used for comparison with clinical disease
populations.
Considering 1) the important role of NO in vascular health,
2) the increased utilization of local skin heating to assess
microvascular function, 3) the conflicting evidence for both
eNOS (18) and nNOS (34) involvement in NO synthesis during
local heating, and 4) possible changes to these mechanisms
with healthy middle aging, the primary aim of this study was to
identify the predominant NOS isoform mediating cutaneous
vasodilation during local heating. A secondary aim was to
determine if there are any changes in these mechanisms with
primary middle-aging. We hypothesized 1) that eNOS would
be the predominant NOS isoform mediating cutaneous vaso-
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dilation during local heating, and 2) that eNOS-mediated
vasodilation would be attenuated in healthy, middle-aged hu-
mans. In addition to functional in vivo studies, in vitro analysis
of skin biopsy samples was also performed to examine NOS
isoform expression and the downstream molecular vasodilatory
target vasodilator-simulated phosphoprotein (pVASP) as an
index of NOS activity.
METHODS
Subjects
All experimental procedures were preapproved by The Pennsylva-
nia State University Institutional Review Board and met the guide-
lines set by the Declaration of Helsinki. Twelve middle-aged and
twelve younger men and women voluntarily participated in the study
after giving written and verbal informed consent. All subjects were
screened prior to participating in the experiment to ensure they were
nonsmokers, and free of dermatologic, metabolic, and cardiovascular
diseases. In addition, all subjects’ blood pressures were monitored for
24 h using an ambulatory blood pressure monitor (Ambulo 2400,
Portland, OR) to ensure they were normotensive. Participants were
normally active and were not taking any cardiovascular medications
or supplements, oral contraceptives, or hormonal replacement therapy.
All women were either postmenopausal or were tested in the low
hormone phase of their menstrual cycles.
Instrumentation and Measurements
Subjects arrived in the room temperature (23°C) laboratory be-
tween 7:00 and 9:00 am dressed in comfortable clothing, typically
exercise pants and a T-shirt for both protocols. Upon arrival subjects
were instrumented with four intradermal microdialysis (MD) fibers
(10 mm, 20-kDa cutoff membrane, MD 2000 Bioanalytical Systems,
West Lafayette, IN) as previously described (32). Once inserted, the
MD agents were perfused at a rate of 2.0 /min (Bee Hive control and
Baby Bee microinfusion pumps; Bioanalytical Systems) for 60–90
min to ensure resolution of local hyperemia from needle insertion
trauma.
In Vivo Analysis of Vascular Function
To obtain an index of skin blood flow, laser-Dopplers were (LDF;
MoorLAB, Temperature Monitor SHO2, Moor Instruments, Devon,
UK) placed in local heating units directly over the membrane portion
of each MD fiber. The local heaters were set at 33°C to clamp local
skin temperature during baseline measurements in the local heating
protocol and throughout the ACh dose-dependent perfusion protocol.
This localized temperature was used to ensure that the changes in
percent of maximal cutaneous vascular conductance (%CVCmax) were
due to the perfusion of ACh. Arterial blood pressure was measured
every 5 min in the right arm throughout the experiment using a
Cardiocap blood pressure monitor and was verified with brachial
auscultation. Mean arterial pressure (MAP) was calculated as the
diastolic blood pressure plus one-third the pulse pressure. CVC was
calculated as red blood cell flux divided by MAP.
Experimental protocols. Pharmacological agents were perfused
during the 60- to 90-min resolution of the local hyperemic response
from needle insertion trauma. After the local hyperemic response
subsided, baseline recordings were measured for 20 min or until the
hyperemic response had subsided. Each subject participated in two
protocols (local heating and ACh perfusion in a dose-dependent
manner) that took place on two different days and were separated by
a minimum of 1 wk. During the protocols MD fiber sites were
randomly assigned 1) lactated Ringer’s solution to serve as control,
2) 20 mM NG-nitro-L-arginine methyl ester (L-NAME; Tocris, Ellis-
ville, MO) to nonselectively inhibit all NOS isoforms (NOS-I), 3) 0.1
mM N-[3-(aminomethyl)benzyl]acetamidine (1400W; Calbiochem,
San Diego, CA) to selectively inhibit iNOS (iNOS-I), and 4) 5 mM
N-propyl-L-arginine (NPLA; Tocris, Ellisville, MO) to selectively
inhibit nNOS (nNOS-I). All inhibitors were dissolved in lactated
Ringer’s solution and were sterilized using syringe microfilters (Ac-
rodisc, Pall, Ann Arbor, MI). The efficacy of the isoform-specific
antagonism and concentrations of the pharmacological agents used in
this study have been demonstrated in other microdialysis studies
(1400W Ki  7 nM, NPLA Ki  57 nM ) (2, 4, 12, 22, 30, 34, 37).
Furthermore, the efficacy of NPLA was also piloted with a whole
body heating protocol in four young subjects to determine if the
concentration used attenuated reflex vasodilation similar to those
reported by Kellogg et al. (15).
Local heating. After 20 min of baseline measurements, the local
heaters were increased at a rate of 0.5°C every 5 s to a temperature of
42°C. The sites were held at 42°C until a stable CVC plateau was
reached (30–40 min). After the stable plateau, while the local heater
temperature was maintained at 42°C 20 mM L-NAME was perfused at
a rate of 4 l/min for 40–50 min at all sites to determine the reduction
in CVC from inhibition of all NOS isoforms. This allowed for the
within-site calculation of the percent reduction in CVC after NOS
inhibition. The total local heating time was between 70 and 90 min.
ACh dose-response. After the baseline measurements ACh perfu-
sion in a dose-dependent manner was performed to assess endothelial
derived eNOS-mediated dilation (12, 20, 27). Just prior to the ACh
perfusion, ACh doses (0.01, 0.1, 1, 5, 10, 50, and 100 mM) were
diluted with the site-specific pharmacological agents. The doses were
administered for 5 min in increasing concentrations (40 min). This
amount of time elicited a stable plateau of at least 3 min. At the end
of each protocol, all sites were perfused with 28 mM sodium nitro-
prusside (SNP; Nitropress, Abbott Laboratories, Chicago, IL) at a rate
of 4 l/min and were locally heated to 43°C to ensure maximal CVC
had been achieved.
In Vitro Analysis of Vascular Function
Ventral forearm skin samples were obtained from the opposite arm
on a separate day from the in vivo functional assessment of vasore-
activity. The skin was anesthetized using 2% lidocaine without epi-
nephrine. Using sterile technique two 3-mm-diameter skin samples
were obtained. Samples were rinsed in lactated Ringer’s and imme-
diately frozen in liquid nitrogen and stored at 80°C until analysis.
Western blot analysis. After centrifugation of skin homogenates
twice at 15,000 g at 4°C for 20 min, protein concentration was
determined using a Bio-Rad DC protein assay. For Western blot
analysis, 25 g (for eNOS and nNOS) and 50 g (for iNOS and
pVASP) proteins were fractionated by SDS/PAGE and electrotrans-
ferred to a nitrocellulose membrane (Hybond-ECL, Amersham Life
Sciences). The membranes were blocked for 1 h at room temperature
(5% nonfat dry milk, in Tris-buffered saline containing 0.1% Tween-
20; TBST) and incubated with a primary antibody to eNOS (Santa
Cruz Biotech; 1:1,000); nNOS (BD Bioscience, 1:1,000); iNOS (BD
Bioscience, 1:1,000); and pVASP (1:1,000; Cell Signaling). Bound
antibody was detected with horseradish peroxidase-conjugated IgG
secondary antibody (1:1,000) (Santa Cruz Biotechnology) and visu-
alized using enhanced chemiluminescence. Next, the pVASP blot was
stripped using Restore Plus Western Blot Stripping Buffer (Thermo
Scientific) and reprobed with VASP antibody (Cell Signaling).
GAPDH was used as loading control. Densitometry analyses were
performed using ImageJ software (NIH).
Data acquisition and statistical analysis. Skin blood flow data were
normalized as a percentage of maximal CVC (%CVCmax). Data were
collected at 40 Hz, digitized, recorded, and stored in a personal
computer until data analysis (Windaq, Dataq Instruments, Akron,
OH). CVC data were averaged over a stable 5 min of baseline, local
heating plateau, post-L-NAME plateau, and maximal vasodilation.
The initial sensory-nerve peak was calculated as the highest average
values (30-s intervals). The vasodilation due to NO at the plateau was
calculated from the difference between the plateau and the post-L-
NAME plateau. CVC for each ACh-dose was averaged over the last
3 min of perfusion of each concentration and normalized to maximal
vasodilation which was obtained from the most stable 5-min period
where skin blood flow had peaked with the infusion of 28 mM SNP
and with simultaneous locally heating to 43°C.
Student’s unpaired t-tests were used to determine significant dif-
ferences between age groups for physical characteristics and the
reduction in NO-mediated dilation after perfusion of L-NAME during
the local heating protocol. Data were initially analyzed using a
three-way mixed model repeated-measures ANOVA (group  micro-
dialysis treatment site  phase of the local heating response or ACh
dose) (SAS, version 9.2, Cary, NC). When the groups were collapsed
data were analyzed using a two-way mixed models repeated-measures
ANOVA (microdialysis treatment site  phase of local heating
response or ACh dose). A priori specific planned comparisons were
performed when appropriate to determine where differences between
groups and localized drug treatments existed. The level of significance
was set at 	  0.05 for main effects. All values are expressed as
means  SE.
RESULTS
Subject characteristics are presented in Table 1. A total of 24
subjects were tested. Age groups were well matched for height,
body mass index (BMI), MAP, and cholesterol ratio (total cho-
lesterol/high-density lipoprotein cholesterol). Absolute maximal
CVC are presented in Table 2. There was no effect of age or
localized microdialysis drug treatment on absolute maximal CVC
(all P  0.05).
During our initial pilot experiments to determine the efficacy
of the nNOS inhibitor NPLA, relative NO-dependent vasodi-
lation (assessed with L-NAME) was attenuated with pretreat-
ment of 5 mM NPLA (control 28  8 vs. NPLA 8 
5%CVCmax).
Figure 1 shows the time course of the local heating response
in a control site from a representative subject. All of the
distinct phases of the response are labeled.
There was no interaction between age and NOS isoform-
specific inhibitor during local heating or ACh dose-response;
therefore, data for both age groups were combined to illustrate
the differences due to specific NOS isoform inhibition. Figure 2
shows the mean data for the distinct phases of the local heating
response in all drug treatment sites. Nonspecific NOS inhibi-
tion with L-NAME decreased baseline (Fig. 2A), the initial
peak (Fig. 2B), and the plateau (Fig. 2C) compared with all
other sites (all P  0.001). iNOS inhibition reduced the
initial sensory nerve-mediated peak (53  2 vs. 60 
2%CVCmax; Fig. 2B, P  0.001), but there were no other
differences between specific NOS-inhibited treatment sites.
Figure 3 illustrates the age-group combined %CVCmax re-
sponse for all drug treatment sites with increasing concentra-
tions of the endothelium-receptor agonist ACh. L-NAME de-
creased %CVCmax across all concentrations of ACh (all P 
0.001). Compared with the control site there were no other
differences with isoform-specific NOS inhibition.
Because there were no differences between sites with spe-
cific NOS isoform inhibition (NPLA and 1400W), data for the
control site for the two age groups are presented in Figs. 4 and 5.
Figure 4 shows the NO-dependent plateau and the post-L-
NAME plateau of the local heating response. A quantification
of total within-site NO-dependent vasodilation is illustrated
with arrows and values provided. There were no differences in
the plateau, but the middle-aged group had an augmented
post-L-NAME plateau. Therefore, the within-site NO-depen-
dent vasodilation was reduced in the middle-aged group (52 
6 vs. 68  4%CVCmax; P  0.013). Figure 5 shows the
%CVCmax response with increasing concentrations of ACh
separated by age. The middle-aged group had attenuated ACh-
induced vasodilation at the highest concentration (100 mmol/l:
83  4 vs. 92  3%CVCmax; P  0.03).
Figure 6 shows densitometric analysis and representative
Western blots of nNOS, iNOS, eNOS, and pVASP from the
skin biopsy samples for both groups. There were no differences
Table 1. Subject characteristics
Young Middle-Aged
Sex, M/W 7/5 3/9
Age, yr 23  1 53  1*
Height, cm 168  3 174  3
Weight, kg 81  5 68  3*
BMI, kg/m2 27  1 25  1
Resting MAP, mmHg 87  2 85  2
Fasting glucose, mg/dl 89  1 85  2
Total cholesterol, mg/dl 148  5 190  5*
LDL, mg/dl 86  7 108  4*
HDL, mg/dl 44  3 61  5*
Cholesterol ratio, total/HDL 3.4  0.3 3.2  0.2
Values are means  SE. M, men; W, women; BMI, body mass index; MAP,
mean arterial pressure; LDL, low-density lipoprotein; HDL, high-density
lipoprotein. *P  0.05: difference vs. young.
Table 2. Absolute maximal cutaneous vascular conductance
Site Young Middle-Aged
Control 1.70  0.22 1.87  0.23
NPLA (nNOS inhibited) 1.94  0.28 1.75  0.18
1400W (iNOS inhibited) 1.92  0.22 1.85  0.23
L-NAME (all NOS inhibited) 1.86  0.21 1.75  0.20
Group means  SE of absolute maximal cutaneous vascular conductance
(flux/mmHg) for the 4 treatment sites in young and middle-aged groups.
NPLA, N
-propyl-L-arginine; L-NAME, NG-nitro-L-arginine methyl ester;
nNOS, neuronal nitric oxide synthase; iNOS, inducible nitric oxide synthase.
Fig. 1. A time course representative tracing of the control site during the local
heating protocol. The baseline, initial peak, plateau, and post-L-NAME plateau
are identified. CVC, cutaneous vascular conductance; L-NAME, NG-nitro-L-
arginine methyl ester.
in eNOS, nNOS, or iNOS expression between the groups.
Further, there was no difference in the downstream vasodila-
tory target pVASP between groups.
DISCUSSION
The principal finding of the present study was that eNOS is
the primary isoform mediating cutaneous NO-dependent vaso-
dilation during local heating and perfusion of the endothelium-
dependent agonist ACh. There was no effect of selective nNOS
or iNOS inhibition compared with the control sites on the
plateau response to local heating or during the ACh dose
response, but there was a significant attenuation when all NOS
isoforms were inhibited with L-NAME. Further, during local
heating iNOS contributed to the sensory nerve-mediated initial
peak suggesting an upregulation in iNOS activity associated
with sensory nerve activation. A secondary finding of the
present study was that deficits in functional NO-dependent
vasodilation can be detected in middle-aged skin. These defi-
cits were only apparent during 1) local heating when NO-
dependent vasodilation was quantified using a within-site per-
fusion of L-NAME and not from a comparison of the plateau
%CVCmax values or 2) at the highest concentration of ACh
(100 mmol/L). There were no differences in NOS isoform
expression or downstream vasodilatory molecular targets
(pVASP), suggesting the modest changes observed in function
are likely due to changes in NO metabolism.
In young human skin there is controversy pertaining to the
precise NOS isoform mediating the production of NO during
the skin local heating response (18, 34). The use of different
pharmacological inhibitors, patient populations, and regional
skin circulations examined contributes to the inconsistent find-
ings with these studies. The results from the present study
suggest that eNOS is the primary NOS isoform mediating the
production of NO during the plateau phase of the local heating
Fig. 2. Mean  SE percentage of maximal CVC (%CVCmax) in baseline (A), the initial peak (B), the plateau (C), and after nonspecific NO synthase (NOS)
inhibition with L-NAME (D) in each microdialysis drug treatment sites. Inducible NOS (iNOS) inhibition with 1400W decreased the initial peak, and nonspecific
NOS inhibition with L-NAME decreased baseline, the initial peak, and plateau during local heating. NPLA, N-propyl-L-arginine; nNOS, neuronal NOS. *P 
0.001 vs. control site.
response in young and middle-aged nonglaborous forearm
skin. This is evidenced from sites treated with the specific
nNOS and iNOS inhibitors having no effect on attenuating the
plateau response and that nonspecific NOS inhibition with
L-NAME at the plateau had a similar effect in all sites. It is
possible that the concentration of the inhibitors used was not
efficacious at blocking the specific NOS isozymes. However,
we used the same concentration of NPLA used by Kellogg et
al. (15), finding similar results during local heating. We also
verified the efficacy of this inhibitor in pilot work using a
whole body heating protocol and observed an attenuation in the
NO-mediated portion of the reflex vasodilatory response. Fur-
thermore, we used the same concentration of 1400W (iNOS
inhibitor) detecting significant effects specific to iNOS mech-
anisms in an essential hypertensive population (32). Together,
these data confirm that the NO-mediated portion of the plateau
response during local heating is likely produced via eNOS-
dependent mechanisms.
One unexpected finding from the present study was that
iNOS inhibition with 1400W reduced the initial sensory nerve-
mediated peak in skin blood flow during local heating. Based
on the putative role of iNOS as an inflammatory mediator that
reduces eNOS-dependent mechanisms (30, 33) we did not
anticipate that iNOS inhibition would attenuate the initial peak
in healthy subjects. The initial peak is partially mediated by
the production of NO, but there is a significant portion that
is due to the release of neurogenic vasodilator peptides
acting on neurokinin 1 receptors including the putative
neurotransmitters substance P and CGRP (36). Moreover, it
appears that adrenergic neurotransmitters also modulate this
response (6). Our data suggest that iNOS-mediated NO
production also contributes to the initial peak. Interestingly,
in other tissues substance P has been shown to augment NO
production through iNOS (13).
In the present study we utilized two skin-specific protocols
to examine possible age-related changes in cutaneous micro-
vascular function. These techniques are increasingly being
utilized to examine mechanisms of microvascular dysfunction
in clinical populations. Many of the disease states under
investigation have an onset in middle-age and therefore clinical
populations are often compared with a healthy middle-aged
cohort. Furthermore, much of the work in the aging literature
has compared a group of subjects of advanced age (65–85 yr)
contrasted to a group of young healthy control subjects (18–30 yr)
(26). In this study we have specifically examined a middle-
aged group (46–57 yr). Our data indicate that deficits in
cutaneous NO-mediated vasodilation can be detected in this
middle-aged population. These deficits only become apparent
when NO-dependent vasodilation is quantified within site by
perfusing L-NAME during the plateau phase of the local
heating response. Without this direct quantification there are no
differences in the absolute plateau phase of the response which
is in contrast to what we observe with advanced age or in
Fig. 3. Mean  SE %CVCmax during an ACh dose response. There was no
effect of selective nNOS or iNOS inhibition. Nonselective NOS inhibition with
L-NAME attenuated %CVCmax at all concentrations of ACh. *P  0.001,
significant difference vs. control site.
Fig. 4. Group mean  SE %CVCmax during the plateau and post-L-NAME
plateau of the local heating response. The post-L-NAME plateau was increased
and total NO-dependent vasodilation, illustrated as the difference between the
plateau and the post-L-NAME plateau was decreased in the middle-aged group
*P  0.013.
Fig. 5. Group mean  SE %CVCmax during an ACh dose response in the
control sites. ACh-induced vasodilation was attenuated in the middle-aged at
the two highest concentrations of ACh; *P  0.03.
hypercholesterolemic (10) or essential hypertensive patients
(32). These data suggest that a secondary NO-independent
pathway is upregulated to compensate for the decrease in NO
with healthy middle aging. In the context of the aging contin-
uum this is an intriguing finding because it appears that the
middle aged are able to compensate and that redundancy is lost
in advanced age.
In middle-aged skin we also observed that endothelium-
dependent vasodilation to the agonist ACh was reduced but
only at the highest concentration tested (100 mmol/l). There
was also no difference in the ACh-dose response in sites
treated with the nonspecific NOS inhibitor L-NAME between
age groups. In contrast, in an essential hypertensive population
of the same age group where there is more clinically significant
endothelial dysfunction we observe an augmented ACh-dose
response in sites continuously treated with L-NAME. Taken
together, these data show that modest age-related changes in
cutaneous microvascular function specific to NO can be de-
tected in healthy middle-aged skin.
In vitro analysis of skin biopsy samples showed that there was
no difference in the expression of the NOS isoforms between age
groups. Furthermore, there was no difference in the downstream
vasodilatory target pVASP/VASP for Ser239, which is the major
site at which the cGMP-dependent kinase PKG phosphorylates
VASP. Functionally we detected modest declines in endothelium-
dependent vasodilation in the middle-aged group. The biochem-
ical expression data do not show a significant difference between
NOS isoform protein content or differences in pVASP between
age groups, but these data are not reflective of mechanisms
affecting NO such as increased oxidant stress. It is not surprising
that we were unable to detect differences in pVASP as these
proteins were measured in unstimulated whole skin homogenates
and functionally only modest differences in eNOS-dependent
vasodilation were measureable.
Limitations
Our aim with the present study was to examine the specific
isoforms mediating cutaneous vasodilation during local heat-
ing. We further wanted to determine if there were any age-
related changes to these mechanisms in middle-aged skin. We
have previously examined similar mechanisms with primary
advanced aging. In the present study it would have been ideal
to have three age groups to determine the age-related changes
along the aging continuum. While we are relying on historical
data collected by our research group for the advanced age
group, this does not detract from our ability to make conclu-
sions about the mild cutaneous microvascular dysfunction that
we measured in the middle-aged group. Moreover, this study
enables us to put these middle-age-related changes in context
with those changes that we observe in other clinical popula-
tions (9, 10, 26, 32).
Fig. 6. iNOS, nNOS-2, endothelial NOS (eNOS)-3, VASP (vasodilator-stimulated phosphoprotein), and pVASP (phosphorylated VASP). Expression of the three
NOS enzymes, and VASP, and pVASP activity were determined by Western blotting. GAPDH was used as loading control. Sample blot is shown in first panel.
Densitometry analysis was performed using ImageJ software (NIH).
We have utilized a standardized (8–10, 24, 26, 32) local
heating protocol to induce NO-dependent vasodilation using
the nonspecific NOS-inhibitor L-NAME to quantify vasodila-
tion due to the production of NO during heating. To do this we
continually heated the skin for 70–90 min. Hodges et al. (5)
noted that with adrenergic blockade that heating for this length
of time resulted in a “die-away phenomenon.” Because we did
not include a time control it is possible that part of what we are
attributing as vasodilation due to NO production may be
accounted for with the die-away phenomenon. However, if this
were the case the error would have been systematic across all
sites and therefore does not change the main interpretation of
the local heating data.
In addition to the functional data collected with isoform-
specific inhibitors, we have analyzed skin samples from the
same subjects to examine NOS isoform protein expression.
Unfortunately, we were not able to measure NOS activity in
these samples because of 1) limited protein recovery from the
skin homogenates and because 2) there are many non-NOS-
dependent endogenous sources of nitrate and nitrite in human
skin resulting from ultraviolent light exposure (28). It would
have also been ideal to obtain Western blot data of phosphor-
ylated eNOS. This would have yielded greater insight into our
results showing attenuated cutaneous vasodilation in middle-
aged skin. However, because of the labile nature of phosphor-
ylated proteins and the time lapse between sample analyses we
were unable to make these measurements.
Finally, our conclusions are based off of establishing the
efficacy of our isoform-specific inhibitors. There is evidence in
knockout animal models and with prolonged isoform-specific
inhibition that other isoforms may be upregulated. We cannot
exclude this as a possibility, although we think it is unlikely
because the relatively short time course of our isoform-specific
inhibition would not be sufficient to observe an increase in
protein expression. With regard to the specific isoform inhib-
itor efficacy we rigorously tested these inhibitors including
performing additional whole body heating experiments to ver-
ify the results of Kellogg et al. (15) and relied on historical data
from other laboratories to determine final inhibitor concentra-
tions. We have also seen efficacious inhibition of iNOS with
this concentration of 1400W in an essential hypertensive pop-
ulation, which was supported with molecular data (32). How-
ever, it is possible that isoform-specific NOS blockade was not
fully achieved. In young subjects our data showed that at the
intermediate concentrations of ACh that NPLA modestly in-
hibited vasodilation. Although we did see attenuation in NO-
dependent vasodilation during reflex heating in our pilot work
with young subjects and no effect on the local heating response
in the present study, these data suggest to us that NPLA at this
concentration may have also partially inhibited other NOS
isoforms, likely eNOS.
Summary
In summary, our main finding was that eNOS is the primary
isoform mediating cutaneous NO-dependent vasodilation dur-
ing local heating and perfusion of the endothelium-dependent
agonist ACh. Using these skin-specific techniques we found
that modest deficits in functional NO-dependent vasodilation
were present in middle-aged human skin. Additionally, NO
derived from iNOS contributed to the sensory nerve-mediated
initial peak. Finally, from the skin biopsy analysis we observed
no differences in NOS isoform expression or downstream
vasodilatory molecular targets suggesting the modest changes
observed in function are likely due to changes in enzyme
activity.
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